Sensus Healthcare, Inc. SRTS
- Market cap
- $47.9M
- P/E
- 0.0×
Follow SRTS
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.67 | 3.38 | 5.00 | 3.31 | 1.76 | 3.08 | 5.58 | 1.79 | 2.37 | 3.03 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 6.69 | 6.25 | 8.88 | 9.23 | 4.99 | 8.55 | 15.25 | 9.62 | 9.33 | 9.08 |
High Price
|
|||
| 37 | 45 | 48 | 53 | 42 | 37 | 42 | 35 | 54 | 60 |
Employees
|
|||
| 0 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
Revenue/Emp
|
|||
| 15 | 21 | 26 | 27 | 10 | 27 | 45 | 24 | 42 | 27 |
Revenue
|
|||
| 66.48% | 67.03% | 63.99% | 64.40% | 54.81% | 62.82% | 66.53% | 57.61% | 58.44% | 43.18% |
Gross Margin
|
|||
| 0 | (4) | (2) | (2) | (7) | 4 | 28 | 1 | 9 | (10) |
EBT
|
|||
| (2.34%) | (18.02%) | (7.65%) | (6.24%) | (71.38%) | 15.23% | 62.85% | 2.67% | 21.58% | (35.02%) |
EBT Margin
|
|||
| 0 | (4) | (2) | (2) | (7) | 4 | 24 | 0 | 7 | (8) |
Net Income
|
|||
| 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
Depreciation
|
|||
| 1.23 | 1.56 | 1.87 | 1.68 | 0.58 | 1.64 | 2.70 | 1.50 | 2.56 | 1.68 |
Revenue/Sh
|
|||
| (0.03) | (0.28) | (0.14) | (0.10) | (0.42) | 0.25 | 1.47 | 0.03 | 0.41 | (0.47) |
Earnings/Sh
|
|||
| (0.07) | (0.23) | (0.61) | (0.13) | (0.03) | (0.02) | (0.09) | (0.13) | (0.05) | 0.03 |
Cash Flow/Sh
|
|||
| (0.02) | (0.02) | (0.06) | (0.02) | (0.02) | 0.01 | 0.90 | (0.01) | (0.02) | (0.01) |
Capex/Sh
|
|||
| (0.09) | (0.25) | (0.67) | (0.15) | (0.05) | (0.01) | 0.81 | (0.14) | (0.07) | 0.02 |
Free CF/Sh
|
|||
| 1.27 | 0.88 | 1.87 | 1.73 | 1.31 | 1.58 | 2.92 | 3.00 | 3.42 | 2.95 |
Book Value/Sh
|
|||
| 12 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.08 | 4.83 | 83.00 | 17.30 | 0.00 |
PE Ratio
|
|||
| 4.26 | 3.66 | 3.96 | 2.11 | 6.62 | 4.40 | 2.61 | 1.66 | 2.70 | 2.36 |
PS Ratio
|
|||
| 4.13 | 6.46 | 3.95 | 2.05 | 2.95 | 4.57 | 2.42 | 0.83 | 2.02 | 1.35 |
PB Ratio
|
|||
| 3.53 | 3.31 | 3.60 | 1.59 | 5.21 | 3.89 | 2.06 | 0.74 | 2.19 | 1.59 |
EV/Sales
|
|||
| (46.02) | (20.36) | (10.09) | (17.31) | (62.94) | (670.84) | 6.83 | (7.79) | (82.79) | 131.72 |
EV/FCF
|
|||
| (1) | (3) | (9) | (2) | 0 | 0 | (1) | (2) | (1) | 1 |
Op' Cash Flow
|
|||
| 0 | 0 | (1) | 0 | 0 | 0 | 15 | 0 | 0 | 0 |
Capex
|
|||
| (1) | (3) | (9) | (3) | (1) | 0 | 13 | (2) | (1) | 0 |
FCF
|
|||
| 13 | 13 | 26 | 28 | 20 | 25 | 46 | 45 | 51 | 41 |
Working Cap'
|
|||
| — | 2 | — | 1 | 1 | 0 | 1 | — | — | — |
Total Debt
|
|||
| (12) | (9) | (15) | (14) | (14) | (14) | (24) | (23) | (22) | (22) |
Net Debt
|
|||
| 15 | 12 | 26 | 28 | 21 | 26 | 48 | 49 | 56 | 48 |
Sh' Equity
|
|||
| (2.42%) | (19.64%) | (7.77%) | (4.84%) | (21.06%) | 13.67% | 54.50% | 0.88% | 11.47% | (13.40%) |
ROA
|
|||
| (6.02%) | (85.89%) | (11.31%) | (8.83%) | (64.56%) | 21.97% | 39.33% | (0.93%) | 14.97% | (24.76%) |
ROIC
|
|||
| (3.27%) | (27.53%) | (10.61%) | (6.24%) | (27.62%) | 17.34% | 65.45% | 1.00% | 12.70% | (14.85%) |
ROE
|
|||
Sensus Healthcare, Inc. peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TLIS Talis Biomedical Corporation | $46.3M | 0.0× | Compare |
| XTNT Xtant Medical Holdings, Inc. | $52.9M | 0.0× | Compare |
| MDAI Spectral AI, Inc. | $53.1M | 0.0× | Compare |
| NNOX Nano-X Imaging Ltd. | $53.4M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SNWV Sanuwave Health Inc. | $41.7M | 3.0× | Compare |
| COCH Envoy Medical, Inc. | $55.4M | 0.0× | Compare |
| RPID Rapid Micro Biosystems, Inc. | $55.7M | 0.0× | Compare |
| TELA TELA Bio, Inc. | $57.3M | 0.0× | Compare |
Sensus Healthcare, Inc. (SRTS) key facts
- Sensus Healthcare, Inc. (SRTS) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- Sensus Healthcare, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, down 34.3% from fiscal 2024.
- Sensus Healthcare, Inc. reported a net loss of $7.7 million, or a loss of $0.47 per share, for fiscal 2025.
- As of September 25, 2026, SRTS traded at $2.94, a market capitalization of $47.9 million.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.8× sales.
- Return on equity was −14.9% and debt-to-equity 0.00.
Sensus Healthcare, Inc. (SRTS) Latest News
20 Aug
Sensus Healthcare Inc. (SRTS) released its Q2 2026 earnings call transcript covering quarterly results, operations and outlook. Earnings transcript supplies financial metrics and guidance that shape near-term market views but rarely shift long-term company trajectory.
17 Aug
Sensus Healthcare Inc. reported strong pipeline progress and a new CPT code during its Q2 2026 earnings call. New CPT code and pipeline strength signal major reimbursement and growth shifts for core operations.
14 Aug
Sensus Healthcare held Q2 2026 earnings call detailing quarterly financial results, revenue, and operational updates. Quarterly earnings call delivers financial metrics and guidance that moderately influence near-term stock sentiment.
13 Aug
Sensus Healthcare reported Q2 results in its earnings call, covering revenue, operations and outlook for SRTS. Quarterly earnings updates deliver financial metrics that moderately shape near-term investor sentiment and valuation.
Sensus Healthcare reported second quarter 2026 financial results and business highlights. Quarterly earnings reports deliver performance metrics that can shift near-term stock sentiment without fundamentally redefining company trajectory.
20 May
Sensus Healthcare (SRTS) encounters shifting targets and 2026 reimbursement changes that alter its operational outlook and market position. New targets combined with 2026 reimbursement changes constitute regulatory shifts likely to significantly alter Sensus Healthcare financial trajectory and investor sentiment.
8 May
Sensus Healthcare reported Q1 financial results, revenue increase, improved profitability, operational updates, and optimistic guidance during its earnings call. Q1 earnings highlights directly influence financial performance and investor sentiment with moderate long-term effects.
Sensus Healthcare, Inc. (SRTS) announces amicable resolution of its commercial dispute with SkinCure Oncology. Amicable dispute resolution eliminates legal overhang, moderately improving operational clarity and investor sentiment.
Sensus Healthcare reported Q1 2026 earnings results and operational updates during its earnings call. Quarterly earnings provide financial metrics and guidance that may influence short-term stock sentiment without major strategic shifts.
7 May
Sensus Healthcare, Inc. (SRTS) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward-looking guidance. Q1 2026 earnings transcript reveals financial performance and strategic outlook likely to significantly sway investor sentiment and stock trajectory.
Sensus Healthcare, Inc. (SRTS) reported first quarter 2026 financial results and business highlights. Quarterly earnings reports with business highlights typically drive significant shifts in investor sentiment and stock trajectory.
27 Mar
Sensus Healthcare, Inc. (SRTS) filed a lawsuit against SkinCure Oncology alleging breach of contract. Lawsuit for breach of contract with key partner could moderately affect revenue and operations.
11 Mar
Sensus Healthcare (SRTS) investment narrative shifts as analyst price targets diverge on 2026 expectations. Diverging analyst targets on 2026 expectations moderately influence SRTS investor sentiment and market perception.
26 Feb
Sensus Healthcare introduces Sensus Link, delivering advanced operating capabilities to the existing SRT-100™ installed base. Sensus Link upgrade to SRT-100 systems enhances core product functionality, likely increasing utilization and revenue from installed base.
18 Feb
Sensus Healthcare, Inc. (SRTS) launched Sensus Healthcare Financial Services to simplify customer acquisition of SRT technology. Launching dedicated financial services directly enables easier SRT technology purchases, significantly boosting sales potential and market expansion.
13 Feb
Sensus Healthcare, Inc. reported its Q4 2025 earnings, highlighting a significant increase in revenue driven by strong demand for its SRTS-1 device. The company also announced plans for new product launches and expansion into international markets. Management expressed optimism about future growth and reiterated its commitment to innovation in skin cancer treatment. The earnings call included insights on operational efficiencies and strategic partnerships aimed at enhancing market presence. The announcement of new product launches and international expansion is likely to significantly impact future growth and market performance.
Sensus Healthcare, Inc. (SRTS) reported its Q4 2025 earnings, highlighting challenges faced in the market, including increased competition and regulatory hurdles. The company is focusing on strategic initiatives to enhance product offerings and improve operational efficiency. Management emphasized the importance of innovation and customer engagement to navigate these challenges and maintain growth. Despite the obstacles, SRTS remains optimistic about future opportunities in the healthcare sector. Challenges and strategic initiatives may moderately influence SRTS's financial performance and competitive positioning.
12 Feb
Sensus Healthcare, Inc. reported its Q4 earnings, highlighting significant growth in revenue and an increase in product demand. The company emphasized its commitment to expanding its market presence and enhancing its product offerings. Management discussed strategic initiatives aimed at improving operational efficiency and customer engagement. The earnings call also addressed future projections and the potential impact of upcoming product launches on overall performance. Significant growth in revenue and strategic initiatives indicate a likely positive shift in the company's trajectory.
Sensus Healthcare, Inc. (SRTS) reported its Q4 2025 earnings, highlighting significant growth in revenue and advancements in product offerings. The company emphasized its commitment to expanding its market presence and enhancing customer satisfaction through innovative solutions. Key financial metrics showed improvement, indicating a positive trajectory for future performance. Management provided insights into strategic initiatives aimed at sustaining growth and addressing competitive challenges in the healthcare sector. Significant growth in revenue and strategic initiatives indicate a likely positive shift in the company's trajectory.
Sensus Healthcare, Inc. reported its fourth quarter 2025 financial results, highlighting the publication of dedicated CPT codes for SRT, which will enhance reimbursement for treating non-melanoma skin cancer. This development is expected to improve patient access to SRT and potentially increase revenue for the company. The financial results reflect the company's ongoing commitment to innovation in skin cancer treatment. The introduction of dedicated CPT codes for SRT is a significant regulatory change that could enhance reimbursement and patient access, impacting future revenue and market positioning.
Sensus Healthcare, Inc. (NASDAQ:SRTS) shareholders have experienced a 36% loss over the past three years, reflecting challenges in the company's stock performance. Despite potential growth opportunities in the healthcare sector, the stock's decline raises concerns about its future trajectory and investor confidence. The significant loss in stock value indicates a moderately noticeable influence on investor sentiment and future performance.
7 Jan
Sensus Healthcare, Inc. has appointed Larry Biscotti to its Board of Directors, enhancing its leadership team. Biscotti brings extensive experience in healthcare and technology, which is expected to contribute positively to the company's strategic direction and growth. The appointment of a new board member with relevant experience may moderately influence the company's strategic decisions and market perception.
2 Jan
Sensus Healthcare, Inc. (SRTS) is highlighted among three penny stocks worth considering due to its innovative skin cancer treatment solutions and potential for growth in the medical device market. The company focuses on non-invasive treatments, which are gaining traction in dermatology. Investors are encouraged to evaluate Sensus alongside other promising stocks, as its unique offerings may position it favorably in a competitive landscape. Sensus Healthcare's innovative approach to skin cancer treatment may moderately influence its market performance and investor interest.
23 Nov
Analysts are expressing concerns about Sensus Healthcare, Inc.'s (SRTS) earnings potential, citing various factors that could threaten future performance. The company's financial outlook appears to be under scrutiny, with indications that market conditions may not favor its growth trajectory. Investors are advised to consider these risks when evaluating SRTS's stock. Concerns raised by analysts suggest a moderately noticeable influence on SRTS's financial performance and market sentiment.
14 Nov
Sensus Healthcare, Inc. has expanded the role of President Michael Sardano to include Chief Commercial Officer. This strategic move aims to enhance the company's commercial operations and drive growth in its market presence. The expansion of leadership roles may influence the company's operational effectiveness and market positioning.
12 Nov
Sensus Healthcare, Inc. has appointed Eric Sachetta to its Board of Directors, enhancing its leadership team with his extensive experience in the medical device industry. Sachetta's background includes significant roles at various healthcare companies, which is expected to contribute to Sensus's strategic direction and growth. The appointment of a seasoned executive may positively influence the company's strategic initiatives and operational effectiveness.
9 Nov
Sensus Healthcare, Inc. (NASDAQ:SRTS) has received a valuation of US$7.50 from analysts following its latest financial results. The company's performance has drawn attention, with analysts assessing its potential in the market based on recent developments. Analysts' valuation reflects a moderately noticeable influence on Sensus Healthcare's market position and financial performance.
7 Nov
Sensus Healthcare, Inc. (SRTS) reported its Q3 2025 earnings, highlighting challenges faced in the market, including increased competition and regulatory hurdles. The company is focusing on strategic initiatives to enhance product offerings and improve operational efficiency. Despite these challenges, management remains optimistic about future growth prospects and is committed to navigating the evolving landscape effectively. Moderate challenges and strategic initiatives could influence financial performance and competitive positioning.
6 Nov
Sensus Healthcare, Inc. (SRTS) reported a loss for Q3 but exceeded revenue estimates. The company's financial performance showed resilience despite challenges, indicating potential for future growth. Investors reacted positively to the revenue figures, which surpassed expectations, suggesting confidence in Sensus's market position and operational strategies. The revenue beat indicates a moderately positive influence on financial performance, though the loss suggests ongoing challenges.
Sensus Healthcare, Inc. reported its financial results for the third quarter of 2025, highlighting key metrics such as revenue growth and net income. The company continues to focus on expanding its product offerings and market presence, aiming to enhance shareholder value. Management expressed optimism about future performance and strategic initiatives. Revenue growth and strategic initiatives indicate a moderately noticeable influence on the company's future performance.